Changzhou Qianhong Biopharma (002550.SZ): Net income in the first half of the year reached 0.183 billion yuan, a year-on-year increase of 53.57%.

Gelonghui Finance · Aug 15 01:33

Changzhou Qianhong Biopharma (002550.SZ) released its H1 2024 report, achieving revenue of CNY 0.856 billion and net income attributable to shareholders of listed companies of CNY 0.183 billion, a YoY increase of 53.57%. Net income attributable to shareholders of listed companies, excluding non-recurring gains and losses, was CNY 0.179 billion, a YoY increase of 60.64%. Basic EPS was CNY 0.1457. The main reason is that the company actively responds to the complex and severe ecological environment of the pharmaceutical industry at home and abroad, timely seizes industry strategic opportunities, firmly implements scientific and rational production-supply-sales intensive management policies, and significantly improves the gross margin levels of the formulation and active pharmaceutical ingredient business compared with the same period last year, while gradually reducing the sales expense ratio. The company's main business performance is good overall.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

千红制药(002550.SZ)：上半年净利润1.83亿元 同比增长53.57%

Changzhou Qianhong Biopharma (002550.SZ): Net income in the first half of the year reached 0.183 billion yuan, a year-on-year increase of 53.57%.

Risk Disclaimer

Statement

千红制药(002550.SZ)：上半年净利润1.83亿元同比增长53.57%